Syndax, Incyte Join Forces to Develop Axatilimab for IPF

Syndax, Incyte Join Forces to Develop Axatilimab for IPF

307436

Syndax, Incyte Join Forces to Develop Axatilimab for IPF

Syndax Pharmaceuticals and Incyte are forming a global partnership to develop and commercialize axatilimab, an investigational therapy for idiopathic pulmonary fibrosis (IPF) and other diseases characterized by excessive scarring. The companies are planning to launch a proof-of-concept Phase 2 clinical trial to test axatilimab in IPF patients early next year. “We are excited to partner with Syndax and for the opportunity to bring another potential treatment to patients with life-threatening conditions,” Hervé Hoppenot, CEO of…

You must be logged in to read/download the full post.